Tick-borne encephalitis virus, known as TBEV, hijacks the internal membrane machinery of host cells to build hidden factories for its own replication, and a growing body of three-dimensional microscopy is beginning to map key steps in that takeover. Multiple research teams have used electron tomography, cryo-electron tomography, and light-sheet fluorescence microscopy to map the virus’s effects from the scale of individual membrane vesicles to entire mouse brains, alongside related three-dimensional brain-mapping work in tick-borne flavivirus models using optical projection tomography. Together, the studies describe a pathogen that reshapes the endoplasmic reticulum and is associated with changes in autophagy- and innate-immune-related pathways in experimental systems used to study neurotropic infection.
What is verified so far
The strongest structural evidence comes from electron tomography of infected cells, which shows that TBEV physically remodels host-cell endoplasmic reticulum membranes into replication compartments consisting of roughly 80-nanometer vesicles sitting inside the ER lumen. These vesicles are not sealed off from the rest of the cell. They are invaginations that retain a pore-like opening to the cytoplasm, a feature confirmed through the same electron tomography workflow. Live-cell RNA-tagging and photobleaching experiments further demonstrated that replicated viral RNA traffics through those pores, giving the virus a controlled channel for exporting genetic material while keeping it shielded from cytoplasmic immune sensors.
When researchers shifted from generic cell lines to human neurons, the picture grew more specific. Electron tomography of TBEV-infected neurons documented virus-induced membrane compartments within rough ER and along neuronal extensions. The same study identified associations between these compartments and autophagy-related structures, raising the possibility that the virus either triggers or exploits the cell’s own degradation machinery. That dual observation, replication organelles plus autophagy engagement, suggests TBEV does not simply build a factory; it also manipulates the host’s quality-control systems.
At the whole-organ level, a team engineered a TurboGFP-expressing TBEV reporter, designated tGFP-TBEV, and combined tissue clearing with light-sheet imaging to map infection across the mouse brain. The fluorescent signal concentrated in specific neuroanatomical pathways and regions rather than spreading uniformly, indicating that the virus follows defined routes through neural circuits. Regions associated with motor control, arousal, and autonomic regulation showed particularly strong signals, a pattern the authors reported in the context of neurotropic disease features studied in experimental encephalitis models.
Separate work using optical projection tomography co-registered with an MRI brain template produced a three-dimensional distribution map of a tick-borne flavivirus, with higher-resolution follow-up modalities reaching down to nanometer scale. That study also showed that type I interferon signaling changes both the brain distribution and cellular tropism of the virus, meaning the host’s innate immune response does not simply suppress infection but actively redirects where and in which cell types the virus can establish itself. In interferon-competent animals, infection was more restricted and shifted toward particular neural populations, whereas interferon-deficient conditions allowed broader, less selective spread.
On the molecular side, multi-proteomic profiling of TBEV-infected cells identified broad proteome, phosphoproteome, and acetylproteome changes. The viral protein NS5 was found to interact with host SIRT1, affecting the DNA damage response and repair pathway, while the structural protein prM influenced autophagy pathways. That work connected specific viral components to host signaling hubs that regulate genome stability and cellular stress responses. The same study also used brain organoids to localize infection in a three-dimensional human tissue model, bridging the gap between flat cell cultures and animal experiments and showing that TBEV preferentially targets neurons over supporting glial cells in this setting.
At the virion level, high-resolution cryo-electron microscopy provided detailed three-dimensional architecture of the TBEV particle and its interaction with a neutralizing antibody, clarifying which surface features are accessible to immune targeting. The envelope protein arrangement, glycoprotein spikes, and antibody binding footprints together outline potential epitopes for vaccine design and therapeutic antibodies. These structural data also help explain how small changes in surface residues might allow the virus to escape antibody recognition without compromising its ability to bind cellular receptors.
More recently, cryo-electron tomography has been applied to infected ex vivo mouse brain tissue to visualize replication organelles alongside maturing virions in native tissue, helping connect the architecture of intracellular replication factories to virion assembly and maturation in situ. By visualizing the continuum from ER-derived vesicles to enveloped virions at the cell surface, this work supports a model in which TBEV assembles and matures within an interconnected membrane system that spans the ER, intermediate compartments, and secretory vesicles.
Collectively, these studies show that TBEV is not a passive occupant of the host cytoplasm. It sculpts the ER into specialized invaginations, interfaces with autophagy, and exploits or reshapes innate immune signaling to determine where in the brain it can thrive. The convergence of cell-level tomography, organoid models, and whole-brain imaging has turned what was once an abstract notion of “neurotropism” into a spatially and structurally defined phenomenon.
What remains uncertain
Despite the depth of these imaging studies, several gaps limit how far the findings can be applied. All of the three-dimensional brain-mapping data comes from mouse models or brain organoids. No published study has yet produced equivalent 3D microscopy maps from clinical human brain samples, so whether the neuroanatomical concentration patterns seen in mice translate directly to human encephalitis cases is an open question. Mouse and human brains differ in size, connectivity, and regional immune profiles, and organoids, while human-derived, lack vascular and immune cell components that shape infection in a living person.
The relationship between ER membrane remodeling and autophagy engagement also lacks a clear causal direction. The neuron-focused electron tomography study documented associations between virus-induced compartments and autophagy-related structures, but whether the virus actively triggers autophagy to benefit its own replication, or whether the host cell mounts autophagy as a failed defense, has not been resolved by imaging alone. Proteomic data showing that prM affects autophagy pathways is consistent with viral manipulation, yet that evidence is correlational and drawn from cell culture rather than intact neural tissue. Disentangling cause and effect will likely require perturbation experiments in which autophagy regulators are selectively inhibited or enhanced while replication organelles are tracked in situ.
The interferon finding, that type I IFN signaling alters brain distribution and cellular tropism, raises a practical question that current data cannot fully answer: does this mean that patients with weaker interferon responses face a fundamentally different pattern of brain damage, or does the virus simply spread more broadly without changing its preferred targets? The optical projection tomography study demonstrated the effect in an animal model, but translating that to clinical risk stratification would require matched human imaging and immunological data that do not yet exist. Longitudinal studies linking interferon pathway genetics or serum biomarkers to MRI or PET readouts in encephalitis patients would be needed to close this gap.
No published work has directly tested whether the 80-nanometer pore connections identified in ER-derived vesicles could serve as drug targets. The hypothesis that small-molecule inhibitors or therapeutic antibodies might plug or destabilize these pores, selectively blocking viral RNA export while sparing bulk ER function, remains speculative. Likewise, while structural data on virion–antibody complexes highlight promising epitopes, there is still limited information on how such antibodies would perform in the complex environment of an infected brain, where access across the blood–brain barrier and potential off-target effects must be considered.
Another unresolved issue is how well current in vitro models capture the contributions of non-neuronal cells. Brain organoids and neuron-enriched cultures emphasize neuronal infection, but animal studies indicate that endothelial cells, perivascular macrophages, and choroid plexus epithelium can all participate in viral spread and persistence. Without comparable high-resolution imaging in human tissue, it is difficult to know whether therapeutic strategies should focus primarily on neurons or on the broader neurovascular unit.
For now, TBEV research sits at an intersection where structural virology, cell biology, and systems-level imaging are tightly linked but not yet fully integrated with clinical practice. The existing data, much of it indexed in resources such as NCBI databases, provide a detailed atlas of how the virus behaves in controlled experimental systems. The next phase will require extending those insights into human disease through careful correlation with patient samples, advanced neuroimaging, and functional studies that test whether disrupting specific viral–host interfaces can meaningfully alter the course of infection.
Until such work is done, the structural and three-dimensional maps should be viewed as a powerful but incomplete guide: they show where TBEV can go and what it builds inside cells, but not yet exactly how to stop it in the human brain.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
